NZ621321B2 - Use of omega fatty acids for treating disease - Google Patents

Abstract

Provided is a combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) formulated for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of EPA and DHA is from 5 mmol to 25 mmol per day, and wherein the molar ratio of EPA to DHA is in the range of from 1:1 to 5: 1. ammal, wherein the combined dosage of EPA and DHA is from 5 mmol to 25 mmol per day, and wherein the molar ratio of EPA to DHA is in the range of from 1:1 to 5: 1.

Description

Use of omega fay acids for treating disease Field of Invention The invention s to the use of eicosapentaenoic acid (EPA) and docosahcxaenoic acid (DHA) for treating e, in particular for the treatment or prophylaxis of certain eye conditions.

Background of Invention The macula is the part ofthe retina which is responsible for sharp vision, due to the presence of a high density of cone photoreceptors. Macular oedema is a condition characterised by swelling of the macula due to leakage from small blood vessels. There is a own ofblood retinal rs with changes in microvascular permeability, which leads to extracellular oedema, photoreceptor damage and loss of vision.

Macular oedema is caused by a wide range of retinal diseases which include: 1) Wet age—related macular degeneration, 2) Diabetic maculopathy, 3) Retinal vascular occlusions (branch or central), 4) Epiretinal membranes, and ) Inflammation within the eye such as after recent eye surgery.

Vision loss associated with the above conditions is due to macular oedema, and the main strategy to reduce visual loss in patients having the above conditions has been the treatment of macular oedema. Age—related macular degeneration is the leading cause of visual impairment and ess in persons over the age of 65 in the world. The condition, which occurs in dry and wet forms, usually affects older adults resulting in a loss on in the centre of the Visual field, due to retina damage. In dry age-related macular degeneration, drusen (cellular debris) builds up between the retina and choroid.

In the more severe wet form, blood s may grow up from the choroid behind the , leading to blood and protein leakage beneath the macula and consequences such as vision loss and detached retinas.

Diabetic retinopathy (also referred to as diabetic pathy) is the most common cause of blindness among adults ofworking age, and es swelling ofthe central part of the retina or the macula. Diabetic retinopathy is caused by changes in the blood s of the retina. For some people with the condition, blood vessels may swell and leak fluid and/or abnormal new blood vessels may grow on the surface of the retina.

Diabetic retinopathy has been classified as having four stages: i) Mild non-proliferative ic retinopathy (in which microaneurysms occur — small areas of balloon-like ng in the blood vessels of the retina); ii) Moderative non—proliferative diabetic retinopathy (in which some blood vessels which nourish the retina are blocked); iii) Severe non-proliferative diabetic retinopathy (in which many more blood vessels are blocked depriving areas of the retina of blood ); and iv) Proliferative diabetic retinopathy (in which the growth of new blood vessels takes place. The blood vessels can leak blood resulting in severe Vision loss and/or blindness).

Diabetic retinopathy is responsible for 12,000 to 24,000 new cases of blindness each year in the USA. Macular oedema affects 14% of patients with diabetes.

Retinal vascular occlusion diseases (e. g. by thrombus formation blocking blood supply in arteries to the retina) are the second most common cause of visual loss due to retinal vascular disease. They affect around 1.1 million people in the USA alone, thus enting a serious public health problem.

Epiretinal membrane is a ion affecting the macula in which a layer of tissue forms across the macula which contracts to create tension, and can lead to macula oedema.

The main strategy to reduce visual loss in these patients has been by treatment with VEGF inhibitors. VEGF inhibitors have revolutionised the way in which patients with wet age-related r degeneration are treated in the last 5 years. Intravitreal injections ofVEGF inhibitors (e.g. Avastin® (bevacizumab), Lucentis® (ranibizumab)) have been used to treat macular oedema, and give visual outcomes superior to us treatments. r, although positive effects are observed whilst patients are on treatment, oedema tends to return when treatment is stopped. nt monthly intravitreal injections lead to better es for patients. However, side effects such as endophthalmitis, retinal tears leading to retinal detachments, vitreous haemorrhages and cataracts are observed with repeated injections.

Intravitreal injections of steroids, such as Kenalog® (triamcinolone) have also been used to treat macular oedema. However treatment effects are usually temporary and therapy needs to be repeated. Intravitreal ds can also cause side effects such as increased intraocular re, cataracts, retinal detachment, vitreous haemorrhages and endophthalmitis. In ic pathy, focal or grid laser photocoagulation is the standard of care for the past 25 years. From the ETDRS study it is known that performing focal or grid laser s the risk of moderate vision loss as compared with no treatment.

However, only 17% ofpatients gained vision. This means that nine patients have to be treated, for one to have ed vision.

Conditions causing damage to l photoreceptors and/or retinal pigment epithelial cells include inherited es such as retinitis pigmentosa and Stargardt’s disease, damage caused by exposure to extreme light, damage associated with surgery (e. g. cataract surgery), damage associated with exposure to chemical toxins (e.g. quinines, such as chloroquine) and other conditions such as macular phy and macular degeneration (e.g. dry age-related macular degeneration).

Dry eyes (also known as dry eye disease, dry eye syndrome) is a condition in which the eyes do not produce enough tears, and can lead to the eyes becoming d or swollen. The condition has been defined as being a multifactorial disease of the tears and ocular e that results in symptoms of discomfort, visual disturbance, and tear flim instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface (The Definition and fication of Dry Eye Disease, Guidelines from the 2007 International Dry Eye Workshop, Lemp and Foulks). Dry eyes can cause irritation, reduced visual acuity, superficial ate keratitis and poor tear break—up time. The disease has been classified based on severity into 4 levels, ranging from levels 1 and 2 (mild), to levels 3 (moderate) and 4 (severe) (The Definition and Classification ofDry Eye Disease, supra).

Known therapies for dry eyes include treatment with artificial tear drops, steroidal and eroidal eye drops, cyclosporine eye drops, use of punctal plugs, use of specialized eyewear, and/or surgery. However, there are still patients with dry eyes who remain very symptomatic despite the use of such treatments.

The use of itions containing omega-3 fatty acids in treating and/or preventing eye conditions has been igated. For example, WO2010/118761 (Bolas Science Limited) discloses processes for preparing certain compositions rich in the omega-3 fatty acid hexaenoic acid (DHA) and which contain only low amounts of phytanic acid. /118761 also discloses the use of those compositions for treating certain eye conditions. US 2009/0226547 (Gilbard & ) discloses a nutritional supplement for eye health sing EPA and DHA together with anti-oxidant and anti— angiogenic components.

However, there remains a need for effective alternative therapies for treating conditions such as macular , conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes.

Summary of the Invention Accordingly, in a first aspect, the invention provides eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, for use in the treatment and/or prophylaxis of a condition selected from the group consisting of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal t epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1.

It has been found by the inventor that significant improvements in the symptoms of those conditions can be achieved using EPA and DHA in the indicated ratios and dosage s. The therapy of the invention is surprisingly effective, even for patients with severe forms of those conditions, and even for patients who are non-responsive or poorly responsive to other therapies. The y of the invention is particularly suitable for oral administration, and so avoids the need for frequent intravitreal injections (associated with other therapies such as VEGF inhibitors and steroids). The use ofEPA and DHA in the indicated ratios and dosage amounts also avoids or reduces the side effects experienced with the known treatments (e.g. endophthalmitis, retinal tears leading to retinal detachments, us haemorrhages and cataracts).

In some preferred ments, the EPA and DHA is for use in the treatment of macular oedema in a patient or patient tion that is poorly responsive or non- responsive to treatment with a VEGF inhibitor. In some preferred embodiments, the EPA and DHA is for use in the treatment of moderate and/or severe dry eyes. In some preferred embodiments, the EPA and DHA is for use in the treatment of dry eyes in a patient or patient population that is poorly responsive or non responsive to treatment with steroid eye drops, artificial tear drops, tear lubricating ointments, steroid ointments, punctual plugs and/or cyclosporine eye drops.

In some embodiments, the EPA and DHA is for use together with a further therapeutic agent, for simultaneous, sequential or separate administration. Preferably the further therapeutic agent is a VEGF inhibitor, a steroid, a carbonic ase inhibitor and/or cyclosporine.

In a second aspect, the invention provides a kit comprising i) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof; and ii) a VEGF inhibitor, a steroid, a carbonic anhydrase tor and/or cyclosporine, wherein the ed dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and n the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. The kit is for use in ng the conditions mentioned above.

In a third aspect, the invention provides a composition comprising eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, and at least one pharmaceutically acceptable excipient, n the molar ratio of EPA (or salt or ester thereof) to DHA (or salt or ester thereof) in the composition is in the range of from 1:1 to 5:1, for use in the ent and/or prophylaxis of a condition selected from the group ting of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells and dry eyes in a mammal, and wherein the composition is for administration in a combined daily dosage ofEPA (or salt or ester thereof) to DHA (or salt or ester thereof) of from 5 mmol to 25 mmol per day. Preferably the composition is for oral stration. Preferably, the composition comprises at least 50 weight % omega-3 fatty acids. Preferably, the ition is substantially free from anti-oxidants. In one embodiment, the composition consists of, per 100g: Table 1 Description of the Drawings Figures 1 to 38 show Optical Coherence Tomography (OCT) scans in patients before, during, and after treatment with EPA and DHA in accordance with the invention.

Figure 39 shows the mean gain in lines of vision (Snellen chart) for patients having macular oedema caused by/associated with wet age-related macular degeneration at various time points following treatment with EPA and DHA.

Figure 40 shows the distribution of the number of lines of vision gained by patients having macular oedema caused by/associated with wet lated macular degeneration at s time points following treatment with EPA and DHA.

Figure 41 shows the distribution for number of lines of vision gained by ts having macular oedema caused by/associated with wet age-related macular ration grouped into categories according to their initial , at various time points following treatment with EPA and DHA.

Figure 42 shows the mean gain in lines ofvision (Snellen chart) for patients having macular oedema caused by/associated with diabetic retinopathy at various time points following treatment with EPA and DHA.

Figure 43 shows the distribution of the number of lines of vision gained by patients having macular oedema caused by/associated with diabetic retinopathy at various time points following treatment with EPA and DHA.

Figure 44 shows the distribution for number of lines of vision gained by patients having macular oedema caused by/associated with diabetic retinopathy d into categories according to their initial vision, at various time points following treatment with EPA and DHA.

Figure 45 shows the mean gain in lines of vision (Snellen chart) for patients having macular oedema caused by/associated with branch l vein occlusions and/or cystoid macular oedema ary to inflammation or surgery, at various time points following treatment with EPA and DHA.

Figure 46 shows the distribution of the number of lines of vision gained by patients having macular oedema caused ociated with branch retinal vein occlusions and/or cystoid macular oedema secondary to inflammation or surgery, at various time points following treatment with EPA and DHA.

Detailed Description of Invention The ion provides eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, for use in the treatment and/or prophylaxis of a condition selected from the group consisting of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of pentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. The use of eicosapentaenoic acid and docosahexaenoic acid, in the indicated ratios and dosages, provides a ularly effective y for those conditions, avoids or reduces the requirement for intravitreal injections associated with VEGF inhibitor and d therapies, and avoids or reduces side effects such as endophthalmitis, retinal tears leading to retinal ments, Vitreous rhages and cataracts associated with those known therapies.

The invention also es the use ofEPA and DHA, or a salt or an ester thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal eceptors and/or retinal pigment lial cells, and dry eyes in a mammal, wherein the combined dosage ofEPA and DHA is from 5 mmol to 25 mmol per day, and wherein the molar ratio of EPA to DHA is in the range of from 1:1 to 5:1.

The invention also provides a method for the treatment and/or prevention of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and diy eyes in a mammal, which comprises administering to the mammal EPA and DHA, or a salt or an ester thereof, wherein the combined dosage ofEPA and DHA is from 5 rmnol to 25 mmol per day, and wherein the molar ratio ofEPA to DHA is in the range of from 1:1 to 5:1. Preferably, the mammal is a human. The method is preferably for treatment and/or prevention of r oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and/or dry eyes in a patient or patient population who have or are at risk of developing at least one of those ions.

EPA and DHA are omega~3 fatty acids. An omega-3 fatty acid is an rated fatty acid containing a final carbon-carbon double bond as the third bond from the alkyl end ofthe molecule (i.e. the end that is remote from the carboxylic acid group). Examples of 3 fatty acids are indicated in Table 2.

Table 2: Omega—3 fatty acids Common name Lipid Chemical name MW name osahexaenoic acid 24:6 (12—3) all-cis-6,9, 12 ,15,18 ,21—tetracosahexaenoic acid 357 Tetracosapentaenoic acid 24 :5 (11-3) all—cis-9,12,15,1 8 ,21-tetracosapentaenoic acid 3 59 Docosahexaenoic acrd' 22:6 (n-3) all—cis—4,7,10,l3,16,19-docosahexaenoic acid 328 (DHA) Docosapentaenoic acid 22:5 (11-3) all-cis-7,10,13,16,19-docosapentaenoic acid 331 (DPA) Eicosapentaenoic acid 20:5 (12-3) all-cis-5,8,11,14,17-eicosapentaenoic acid 302 (EPA) Eicosatetraenoic acid 20:4 (11—3) all—cis-S 11 14 17 eicosatetraenmc acrd 304 (ETA) Eicosatnenoic acid (ETE) 20:3 (72-3) all-cis-ll 14,17-eicosatrienoic acid U.) 06 Stearidonic acid (SDA) 18:4 (11-3) all-cis 6,9,12 15 octadecatetraenorc acrd 276 a-Linolenic acid (ALA) 18:3 (72-3) all-cis—9,12,15 octadecatrrenorc acrd 27 00 Hexadecatrienoic acid 16:3 (11—3) s-7,10,13-hexadecatricnoic acid 25 In some embodiments, the EPA and/or DHA is in the form of a salt. Suitable salts include those formed with organic or nic bases. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts, for example those of potassium and sodium, ne earth metal salts, for example those of calcium and magnesium, and salts With organic bases, for example dicyclohexylamine, N—methyl-D-glucomine, morpholine, thiomorpholine, dine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl—, tert-butyl-, diethyl-, diisopropyl-, triethy1-, tributyl- or dimethyl- propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine.

In other embodiments, the EPA and/01' DHA is in the form of an ester. Ester groups e those formed from the terminal carboxylic acid moiety of the omega-3 fatty acid and an alcohol, such as a C142 alkyl ester, formed by on ofthe omega-3 fatty acid with an alcohol having from 1 to 12 carbons, preferably a CM alkyl ester formed by reaction ofthe omega-3 fatty acid with an alcohol having from 1 to 6 carbons, for example a methyl, ethyl, n-propyl, isopropyl, butyl, pentyl, or hexyl ester, formed by reaction of the omega-3 fatty acid with methanol, ethanol, n-propanol, iso-propanol, butanol, pentanol or hexanol. Preferably, the ester is an ethyl ester or a methyl ester, more preferably an ethyl ester.

In one preferred embodiment the EPA or salt or ester thereof comprises EPA and/or EPA ethyl ester, and the DHA or salt or ester thereof comprises DHA and/or DHA ethyl ester. More preferably, a combination of eicosapentaenoic acid and docosahexaenoic acid is used (i.e. the free acids of EPA and DHA are used, rather than salts or esters).

The therapy of the invention has been shown to be ularly effective for treatment of the indicated ions. Thus, preferably the EPA and DHA, or a salt or an ester thereof, are for use in the treatment of a condition selected from macular oedema, conditions g damage to retinal photoreceptors and/or retinal t epithelial cells, and dry eyes. However, the invention also encompasses the use of EPA and DHA in the indicated ratios and dosages as a prophylactic therapy.

In a preferred embodiment, the condition is macular oedema. In a preferred embodiment, the condition is cystoid macular oedema. In a preferred embodiment, the condition is diabetic r oedema. In a preferred embodiment, the condition is macular oedema caused by/associated with wet age-related macular degeneration, ic retinopathy, retinal vascular ions, epiretinal membranes, inflammation in the eye causing oedema and/or retinal pigment epithelial atrophy in a mammal, preferably wet age-related macular degeneration, ic retinopathy, retinal vascular occlusions and/or inflammation ofthe eye. In one embodiment, the condition is r oedema caused by/associated with wet age-related macular degeneration. In r embodiment, the condition is macular oedema caused by/associated with diabetic retinopathy, preferably erative diabetic retinopathy. In another embodiment, the condition is macular oedema caused by/associated with retinal vascular ions. In another embodiment, the condition is macular oedema caused by/associated with epiretinal membranes. In another embodiment, the condition is macular oedema caused by/associated with inflammation of the eye. In another embodiment, the condition is macular oedema caused by/associated with retinal pigment epithelial atrophy.

In a red embodiment, the EPA and DHA, or salt or ester thereof, is for use in the treatment of macular oedema in a patient or patient population that is poorly responsive or non-responsive to treatment with a VEGF inhibitor. Examples ofVEGF inhibitors include Lucentis® (ranibizumab) and Avastin® (bevacizumab). In another embodiment, the EPA and DHA, or salt or ester thereof, is for use in the treatment of macular oedema in a patient or patient population that is poorly responsive or non- sive to treatment with a steroid. Examples of steroids include g® (triamcinolone).

Administration ofEPA and DHA has been shown to result in improved vision mined by a gain in lines on a Snellen chart) in patients who have macular oedema, or a reversal or partial reversal in vision loss associated with/caused by r oedema.

Accordingly, in certain embodiments, the EPA and DHA, or salt or ester thereof, finds use in improving visual acuity in patients who have macular oedema and/or finds use reducing or reversing Vision loss associated with/caused by macular oedema. Patients with macular oedema treated with EPA and DHA have also demonstrated reduced l fluid levels and/or reduced retinal ng. In certain embodiments, the EPA and DHA, or salt or ester thereof, finds use in reducing retinal fluid levels in ts who have macular oedema. In certain embodiments, the EPA and DHA, or salt or ester thereof, finds use in reducing retinal swelling in patients with macular oedema.

In a preferred embodiment, the condition is dry eyes. The therapy ofthe invention has been shown to be particularly effective in treating patients with more severe forms of that condition. Accordingly, in a preferred ment the condition is te or severe dry eyes (i.e. dry eyes of disease severity level 3 or 4). More preferably, the condition is severe dry eyes (i.e. dry eyes of disease severity level 4). In a red embodiment, the EPA and DHA, or salt or ester thereof, is for use in the ent of dry eyes in a patient or patient population that is poorly responsive or non- responsive to treatment with steroid eye drops, artificial tear drops, tear lubricating ointments, steroid ointments, punctual plugs and/or cyclosporine eye drops.

In a preferred embodiment, the ion is a condition causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, e. g. an inherited disease (such as retinitis pigmentosa or Stargardt’s disease), an eye tumour, damage caused by exposure to extreme light, damage associated with surgery (e.g. cataract surgery), damage associated with exposure to al toxins (e.g. es, such as chloroquine) or other conditions such as macular dystrophy, macular degeneration (e.g. dry age—related macular degeneration), optic neuropathy, and vascular disturbance. More preferably, the condition is selected from the group consisting of retinitis pigmentosa, Stargardt’s disease, damage caused by exposure to e light, damage associated with surgery, damage associated with exposure to a chemical toxin, macular dystrophy and dry age- related r degeneration.

Administration ofEPA and DHA has been shown to result in ed vision (as determined by a gain in lines on a Snellen chart) in patients having eceptor damage following cataract surgery or due to chloroquin therapy, or a reversal or partial reversal in vision loss caused by cataract y and/or chloroquin therapy. ingly, in certain embodiments, the EPA and DHA, or salt or ester thereof, finds use in improving visual acuity in patients who have a condition causing damage to l photoreceptors and/or retinal pigment epithelial cells (e.g. photoreceptor damage following cataract surgery, or ing quinine therapy) and/or finds use reducing or reversing vision loss associated with/caused by those conditions.

The combined dosage ofEPA and DHA, or a salt or an ester thereof, is from 5 mmol to 25 mmol per day (for an adult human). Preferably, the combined dosage is from mmol to 20 mmol per day, more preferably from 6 mmol to 18 rmnol, still more preferably from 7 mmol to 17 mmol. In one preferred embodiment, the combined dosage of EPA and DHA, or a salt or an ester thereof, is about 7 mmol to 8 mmol per day. In another preferred ment, the combined dosage ofEPA and DHA, or a salt or an ester thereof, is about 10 mmol to 11 mmol per day. In another preferred embodiment, the combined dosage ofEPA and DHA, or a salt or an ester thereof, is about 16 mmol to 17 mmol per day. In another embodiment, the combined dosage ofEPA and DHA, or a salt or an ester thereof, is from 5 mmol to 15 mmol per day.

The molar ratio of EPA to DHA, or a salt or ester f, is in the range of from 1:1 to 5:1. Preferably the molar ratio is in the range of from 1:1 to 4:1, more preferably 1:1 to 3: 1, still more preferably 1.5:1 to 25:1, yet more preferably 2.1:1 to 24:1, most preferably in the range of from 2.1 :1 to 2.2: 1.

The ratio ofEPA to DHA may alternatively be expressed in terms of a weight ratio. Preferably, EPA and DHA are present in a weight ratio of from 1:1 to 4:1, more preferably from 1:1 to 3:1, most preferably about 2:1.

Preferably, the dosage of EPA, or a salt or an ester thereof, is in the range of from 4 mmol per day to 15 mmol per day, and the dosage of DHA, or a salt or an ester thereof, is in the range of from 2 mmol per day to 7.5 mmol per day. In one red embodiment, the dosage of EPA, or a salt or an ester thereof, is in the range of from 5 mmol per day to 6 mmol per day, and the dosage of DHA, or a salt or an ester thereof, is in the range of from 2 mmol per day to 3 mmol per day. In another preferred embodiment, the dosage of EPA, or a salt or an ester thereof, is in the range of from 7.2 mmol per day to 8.2 mmol per day, and the dosage ofDHA, or a salt or an ester thereof, is in the range of from 3 mmol per day to 4 mmol per day. In another preferred embodiment, the dosage of EPA, or a salt or an ester thereof, is in the range of from 10.5 mmol per day to 11.5 mmol per day, and the dosage of DHA, or a salt or an ester thereof, is in the range of from 4.6 mmol per day to 5.6 mmol per day.

The omega fatty acids EPA and DHA, or salts or esters thereof, may be administered simultaneously, sequentially or tely. Whilst those omega fatty acids may be used as the sole active ingredients in a medicament, it is also le for them to be used in combination with one or more further active ingredients, for simultaneous, sequential or separate administration. Such further active ingredients may be an agent useful in the prevention or ent of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and/or dry eyes. Such agents are known in the art. Preferably the further therapeutic agent is selected from the group consisting of a VEGF inhibitor (such as bevacizumab or ranibizumab), a steroid (such as triarncinolone), a carbonic anhydrase inhibitor (such as acetazolamide, methazolamide or dorzolamide), and cyclosporine. More preferably, the further active ingredient is a VEGF tor and/or a steroid. In one preferred embodiment, the further active ient is a VEGF inhibitor, such as bevacizumab or ranibizumab. In one preferred embodiment, the further active ingredient is a d, such as triamcinolone.

The precise dosage of the further active ingredient will vary with the dosing schedule, the oral potency of the particular agent , the age, size, sex and ion of the t, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance, but can be readily determined by the caregiver or clinician. An appropriate amount can be determined by routine experimentation from animal models and human clinical s. For humans, an ive dose will be known or otherwise able to be determined by one of ordinary skill in the art.

The individual components of such combinations can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The t invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term “administering” is to be interpreted accordingly. It will be understood that the scope of combinations ofthe omega—3 fatty acids EPA and DHA with other agents includes in principle any combi- nation with any pharmaceutical composition useful for treating macular oedema, conditions causing damage to l photoreceptors and/or retinal t epithelial cells, and/or dry eyes.

The above further therapeutic agent, when employed in combination with the omega-3 fatty acids EPA and DHA, may be used, for example, in those amounts indicated in the Physicians‘ Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art.

The present invention also provides a kit comprising i) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester f and ii) a VEGF inhibitor (e.g. bevacizumab or ranibizumab), a steroid (e. g. triamcinolone), a carbonic anhydrase inhibitor (such as acetazolamide, methazolamide or dorzolamide), and cyclosporine, n the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. The kit is for use in treating and/or preventing one or more of the conditions mentioned above.

The y comprising EPA and DHA, or salts or esters thereof, is preferably for oral administration. A treatment that does not require administration of therapeutic agents via intravitreal administration is particularly advantageous. The stration regime is thus greatly simplified compared to treatment with known agents and is likely to lead to improved patient compliance.

The medicament of the invention may advantageously be stered in a single daily dose, or the total daily dosage may be administered in doses oftwo, three or four times daily. Preferably, the EPA and DHA, or a salt or an ester thereof, is for administration once per day or twice per day.

In one preferred ment there is provided EPA and DHA, or a salt or an ester thereof, for use in the treatment of a condition selected from the group consisting of macular oedema, conditions causing damage to l photoreceptors and/or retinal pigment epithelial cells and dry eyes in a mammal, wherein the dosage ofEPA (or salt or ester thereof) is from 4 to 15 mmol per day and wherein the dosage ofDHA (or salt or ester thereof) is from 2 to 7.5 mmol per day. In another red embodiment there is provided EPA and DHA, or a salt or an ester thereof, for use in the treatment ofmacular oedema in a mammal, wherein the dosage of EPA (or salt or ester thereof) is from 4 to 15 mmol per day and wherein the dosage ofDHA (or salt or ester thereof) is from 2 to 7.5 mmol per day. In one preferred embodiment, the condition is macular oedema in a patient or patient population that is poorly responsive or sponsive to treatment with a VEGF inhibitor. In another preferred embodiment, the condition is macular oedema in a t or patient population that is poorly responsive or non-responsive to treatment with a steroid.

In another preferred embodiment there is ed EPA and DHA, or a salt or an ester thereof, for use in the treatment of dry eyes in a mammal, wherein the dosage of EPA (or salt or ester thereof) is from 4 to 15 mmol per day and wherein the dosage of DHA (or salt or ester thereof) is from 2 to 7.5 mmol per day. More preferably the condition is moderate and/or severe dry eyes.

In r preferred embodiment there is provided EPA and DHA, or a salt or an ester thereof, for use in the treatment of conditions causing damage damage to retinal photoreceptors and/or l pigment epithelial cells in a mammal, wherein the dosage of EPA (or salt or ester thereof) is from 4 to 15 mmol per day and wherein the dosage of DHA (or salt or ester f) is from 2 to 7.5 mmol per day.

In another preferred ment, there is provided EPA and DHA for use in the treatment and/or prophylaxis of a condition selected from the group ting of r oedema and dry eyes in a mammal, wherein the combined dosage ofEPA and DHA is from 5 mmol to 25 mmol per day (more preferably from 5 mmol to 15 mmol per day), and wherein the weight ratio ofEPA to DHA is in the range of from 1:1 to 4:1 (more preferably from 1:1 to 3:1, most preferably about 2: 1), In another preferred embodiment, there is provided EPA and DHA, for use in the treatment of a condition selected from the group consisting of macular oedema and dry eyes in a mammal, wherein the combined dosage ofEPA and DHA is from 5 mmol to 25 mmol per day (more preferably from 5 mmol to 15 mmol per day), and wherein the Weight ratio ofEPA to DHA is in the range of from 1:1 to 4:1 (more preferably from 1:1 to 3:1, most preferably about 2:1).

In another preferred embodiment, there is provided EPA and DHA for use in the treatment ofmacular oedema in a mammal, wherein the combined dosage ofEPA and DHA is from 5 mmol to 25 mmol per day (more preferably from 5 to 15 mmol per day), and wherein the weight ratio ofEPA to DHA is in the range of from 1:1 to 4:1 (more preferably from 1:1 to 3:1, most preferably about 2:1).

In r preferred embodiment, there is provided EPA and DHA for use in the treatment of dry eyes in a mammal wherein the combined dosage ofEPA and DHA is from 5 mmol to 25 mmol per day (more ably from 5 to 15 mmol per day), and wherein the weight ratio ofEPA to DHA is in the range of from 1:1 to 4:1 (more preferably from 1:1 to 3:1, most preferably about 2:1).

The invention also provides a composition sing eicosapentaenoic acid (EPA) and docosahexaencic acid (DHA), or a salt or an ester thereof, and at least one pharmaceutically acceptable excipient, wherein the molar ratio ofEPA (or salt or ester thereof) to DHA (or salt or ester thereof) in the composition is in the range of from 1:1 to 5:1, for use in the treatment and/or prophylaxis of a condition selected from the group consisting of r oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells and dry eyes in a mammal, and wherein the composition is for administration in a combined daily dosage of EPA (or salt or ester thereof) to DHA (or salt or ester thereof) of from 5 mmol to 25 mmol per day .

Preferred pharmaceutical formulations useful according to the invention are those suitable for oral administration, and include compositions in liquid or solid form. Where the formulation is a solid composition it may be, for example, in the form of a capsule, caplet, tablet, pill, lozenge or powder. Preferably, the formulation is a composition having liquid form, and most ably the composition is a liquid that is le for oral stration. Liquid compositions may be provided in unit-dose or multi-dose containers such as bottles, vials or ampoules. Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the 3 fatty acids.

Preferably the ition comprises EPA and/or EPA ethyl ester, and ses DHA and/or DHA ethyl ester. More preferably, the composition comprises eicosapentaenoic acid and docosahexaenoic acid (i.e. the free acids ofEPA and DHA are used, rather than salts or esters).

Preferably, the composition comprises eicosapentaenoic acid and docosahexaenoic acid in a molar ratio of from 1:1 to 4:1, more preferably 1:1 to 3:1, still more preferably 1.5:1 to 25:1, yet more preferably 2.1:1 to 24:1, most preferably from 2.111 to 2.2: 1. ably, the composition comprises eicosapentaenoic acid and docosahexaenoic acid in a weight ratio of from 1:1 to 4: 1, more preferably from 1:1 to 3: 1, most preferably about 2:1.

Preferably, the composition comprises at least 30 weight % omega-3 fatty acid, more ably at least 40 weight % omega—3 fatty acid, still more preferably at least 50 weight % omega-3 fatty acid. Preferably, the composition comprises at least 40 weight % of a combination of eicosapentaenoic acid and docosahexaenoic acid in a weight ratio of from 1:1 to 4:1, ally in liquid form, more preferably at least 50 weight % of a ation of eicosapentaenoic acid and docosahexaenoic acid in a weight ratio of from 1:1 to 4: 1, optionally in liquid form. In one particularly preferred embodiment, the composition comprises about 60 weight % of a combination of eicosapentaenoic acid and hexaenoic acid in a weight ratio of about 2: 1, optionally in liquid form.

In one preferred ment, the composition is substantially free from anti- oxidants ed from the list consisting of vitamin E (including tocopherols and tocotrienols), epigallocatechin—3 -gallate (EGCG), vitamin C, lutein and zeaxanthin. In one preferred embodiment, the composition is substantially free from anti—oxidants. In one preferred embodiment, the composition contains no anti-oxidants.

In one embodiment the composition consists of, per 100g: Table 3 Other omega-3 fatty acid 15 g The composition of Table 3 is referred to as Omega 3RX®, and may be provided in liquid form. In certain preferred ments the composition is Omega 3RX®, and the dosage is from 5 ml to 10 ml per day (for e about 5 m1, about 6 ml, about 7 ml, about 8 ml, about 9 ml, or about 10 ml per day). Preferably the Omega 3RX® is for stration once per day or twice per day (e.g. for twice daily closing, 2 doses of 2.5m1, 2 doses of 3 ml, 2 doses of 3.5 m1, 2 doses of 4 ml, 2 doses of 4.5 ml or 2 doses of ml may be administered).

In one preferred ment there is provided a composition comprising EPA and DHA, or a salt or an ester thereof, and at least one pharmaceutically acceptable ent, wherein the molar ratio of EPA (or salt or ester thereof) to DHA (or salt or ester thereof) in the composition is in the range of from 1.521 to 2.5:] (more ably 2.1:1 to 2.4: 1 , most preferably from 2.1:1 to 2.2: 1), for use in the treatment of a condition selected from the group consisting of macular oedema, conditions causing damage to retinal eceptors and/or retinal pigment epithelial cells and dry eyes in a mammal, and wherein the composition is for administration in a ed daily dosage ofEPA (or salt or ester thereof) to DHA (or salt or ester thereof) of from 5 mmol to 25 mmol per day (more preferably from 5 to 15 mmol per day).

In one preferred embodiment there is provided a composition comprising EPA and DHA, or a salt or an ester thereof, and at least one pharmaceutically acceptable excipient, wherein the molar ratio of EPA (or salt or ester thereof) to DHA (or salt or ester thereof) in the composition is in the range of from 1.521 to 25:1 (more ably 2.1:1 to 2.421, most preferably from 2.121 to 2.2: 1), for use in the treatment of macular oedema in a mammal, and wherein the composition is for administration in a combined daily dosage ofEPA (or salt or ester thereof) to DHA (or salt or ester thereof) of from 5 mmol to 25 mmol per day (more preferably from 5 to 15 mmol per day). In one preferred embodiment, the composition is for use in the treatment of macular oedema in a patient or patient population that is poorly responsive or non-responsive to treatment with a VEGF inhibitor. In another preferred embodiment, the composition is for use in the treatment ofmacular oedema in a patient or patient population that is poorly responsive or non-responsive to treatment with a steroid.

In one preferred embodiment there is provided a ition comprising EPA and DHA, or a salt or an ester thereof, and at least one pharmaceutically acceptable excipient, wherein the molar ratio ofEPA (or salt or ester thereof) to DHA (or salt or ester thereof) in the composition is in the range of from 1.5:1 to 2.5:1 (more preferably 2.1:1 to 2.4: 1, most preferably from 2.1:1 to 2.2: 1), for use in the treatment of conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells in a mammal, and wherein the composition is for administration in a combined daily dosage of EPA (or salt or ester f) to DHA (or salt or ester thereof) of from 5 mmol to 25 mmol per day (more preferably from 5 to 15 mmol per day).

In one preferred embodiment there is provided a composition comprising EPA and DHA, or a salt or an ester thereof, and at least one pharmaceutically acceptable excipient, wherein the molar ratio ofEPA (or salt or ester thereof) to DHA (or salt or ester thereof) in the composition is in the range of from 1.521 to 2.521 (more preferably 2.1:1 to 24:1, most preferably from 2.1 :1 to 2.2: l), for use in the treatment of dry eyes in a mammal, and wherein the ition is for stration in a combined daily dosage of EPA (or salt or ester thereof) to DHA (or salt or ester thereof) of from 5 mmol to 25 mmol per day (more preferably from 5 to 15 mmol per day). More preferably, the condition is moderate and/or severe dry eyes.

In one ment there is provided a composition comprising EPA and DHA in a weight ratio of from 1:1 to 4:1, and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prophylaxis of a condition ed from r oedema and dry eyes in a mammal, wherein the composition ses at least 50 weight % 3 fatty acid. In another embodiment there is provided a ition comprising EPA and DHA in a weight ratio of from 1:1 to 4:1, and at least one pharmaceutically acceptable excipient, for use in the treatment of a condition selected from macular oedema and dry eyes in a mammal, wherein the composition comprises at least 50 weight % omega-3 fatty acid.

In another embodiment there is provided a composition comprising EPA and DHA in a weight ratio offrom 1 :1 to 4:1, and at least one pharmaceutically acceptable excipient, for use in the treatment of macular oedema in a mammal, in a patient or patient tion that is poorly responsive or non-responsive to treatment with a VEGF inhibitor and/or a steroid, wherein the composition comprises at least 50 weight % omega-3 fatty acid. In one embodiment, the patient or patient population is poorly responsive or non-responsive to treatment with a VEGF inhibitor. In another embodiment, the patient or patient population is poorly responsive or non-responsive to treatment with a steroid.

It should be understood that in addition to the ingredients particularly mentioned above, the ations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include ing agents.

The following non-limiting es illustrate the invention.

Omega fatty acid composition An example omega fatty acid composition is indicated in Table 4 below and is sold under the name Omega 3RX® (Enerzona): Table 4 Ofwhich: EPA (eicosapentaenoic acid) 40 g DHA (docosahexaenoic acid) 20 g Other omega-3 fatty acid 15 g ml ofOmega 3RX® contains 3.13g of omega-3 fatty acids, of which 1.67g is EPA (5.53 mmol), 0.83g is DHA (2.53 mmol), and 0.63 g is other omega-3 fatty acids.

Example 2 Case studies showing treatment of macular oedema with omega fatty acids 14 cases of r oedema that demonstrate the cy of orally taken Omega 3RX® for treatment are presented.

The omega fatty acids were given orally. The form of omega fatty acid used was Omega 3RX®, in liquid form. Omega 3RX® was dosed twice per day. The daily dose of Omega 3RX® was 5-7 ml (i.e. two doses of 2.5-3.5m1 Omega 3RX® daily).

OCT (Optical Coherence Tomography) can accurately measure the oedema in the macular area and has become an invaluable tool for assessment and therapeutic decision making for patients with macular oedema. OCT scans were used to monitor patients’ response to treatment.

Case 1 Presentation Patient 1 is a 61 year old gentleman with diabetes who was treated for r oedema since 28/9/09.

Treatment He was treated with intravitreal injections ofLucentis® and Kenalog® in 9 and 5/5/10 in the left eye. He also had grid laser treatment on 2/6/10. On 4/8/10 he was started on Omega 3RX®.

Result There was marked improvement in r oedema and Visual acuity in the left eye. Fig. 1 shows the macular oedema before treatment with Omega 3RX® and Fig. 2 after treatment. The vision improved from 6/18 to 6/12 in the left eye.

Case 2 Presentation Patient 2 is a 65 year old gentleman who presented in March 2008 with bilateral pigment epithelial ment (PED, a type of age-related macular degeneration (AMD)).

His Visual acuities were 6/18 right eye and 6/12 left eye.

Treatment From March 2008 until January 2010 he was treated with intravitreal ions of anti-VEGF (Avastin®). He had twelve injections in each eye. In four of the times anti- VEGF was combined with a steroid injection (Kenalog® 2 mg). In March 2010 he was started on Omega 3RX® 2.5ml twice per day. .10 Result On the 3rd ofMarch 2010 his Visual acuites were 6/12 right eye and counting fingers in the left eye. There was l to moderate improvement ofmacular oedema in each eye with each itreal ion but the oedema returned one to two months ing treatment with injections. There was never complete resolution of macular oedema while he was treated with intravitreal injections. Since he was started with Omega 3RX® the macular oedema gradually reduced and completely resolved in both eyes over a period of 2-4 months. He has been without any macular oedema since May 2010 in the right eye and since June 2010 in the left eye.

Ciscfi.

Presentation Patient 3 is a 73 year old lady who presented with choroidal neovascular membrane (wet AMD) in June 2008 in her right eye. Her Visual acuities at presentation were 6/36 in the right eye and 6/6 in the left eye.

Treatment She was treated with intravitreal anti-VEGF injections (Lucentis®) on 9/6/08, 9/7/08, 6/8/08, 5/1/09, 2/2/09, 30/12/09, 0, and 1/3/10. She was started on Omega 3RX® on 26/7/10.

Res—HMS Good short term results were achieved with tion of macular oedema. This patient needed many repeat intravitreal anti-VEGF injections. The visual acuities in the right eye on 26/7/10 was counting fingers. It was decided not to proceed with any r injections and she was started on Omega 3RX®. OCT scan showed marked improvement of macular oedema between the period of 26/07/10 and 29/11/10 (Figures not shown).

Vision improved from counting fingers to 3/60.

Case 4 Presentation Patient 4 is a 78 year old gentleman who presented on 22/3/10 with reduced vision in the right eye. On examination he had right choroidal neovascular membrane (wet AMD) and Visual acuity of 3/60.

Treatment He was treated with ed itreal anti-VEGF and steroid (Lucentis® and Kenalog®) on 22/3/10, 21/4/10, 19/5/10, 16/6/10, 0, and 11/8/10. He was started on Omega 3RX® on 6/10/10.

RLultS.

There was marked reduction of macular oedema (and PED) since the treatment with Omega 3RX® and improved visual acuity. His Visual acuity in this eye was 6/36 in 0 (Figure not shown), 6/18 in 16/6/10, 6/18 in 6/10/10 (Figure not shown), 6/12+2 in 3/11/10 and 6/9+2 in l/12/10 (Figure not . This marked improvement occurred within two months of starting the ent.

CASE Presentation Patient 5 is a 58 year old gentleman who has insulin dependent diabetes. He presented on 19/3/08 with reduced Vision in both eyes due to macular oedema.

Treatment He was d with six intravitreal injections of Lucentis® and Kenalog® in the right eye and five intravitreal injections of Lucentis® and Kenalog® in the left eye from the period ofMarch 2008 to January 2010. Grid laser treatment was performed twice in each eye in 2008 and 2009. He was started on Omega 3RX® on 13/9/10.

Results There was marked improvement of macular oedema in both eyes since the treatment with Omega 3RX®. Complete resolution ofthe oedema in both eyes was observed (Figure not shown). Visual acuity in the right eye remained 6/60 probably due to long standing oedema causing damage to the photoreceptors. In the left eye visual acuity ed from 6/24 in 13/9/10 to 6/12 in 24/11/10.

Case 6 tation t 6 is a 41 year old gentleman with insulin diabetes who presented on 26/4/10 with macular . The macular oedema was at the fovea and not possible for focal laser treatment. His vision was 6/12 in the right eye.

Treatment He had intravitreal ion of Lucentis® with Kenalog® on 26/4/10. On 30/6/10 he was started on Omega 3RX®.

RLUIE Intravitreal injection ntis® with Kenalog® did not resolve the macular . His Vision was 6/12 on 26/4/10 and worsened to 6/12 on 26/5/10. On 30/8/10 his Vision was 6/6 and there was marked improvement ofmacular oedema. Gradual reduction of macular oedema was observed (Figures not shown).

Presentation Patient 7 is a 69 year old gentleman who had a right branch retinal vein occlusion in 2002 and left branch retinal vein occlusion in 2003. He had a scar in the right macular and macular oedema in the left eye.

Treatment He was treated with 3 intravitreal injections ofAvastin® and Kenalog® in the left eye over the periods fiom 10/11/08 to 6/5/09 with no improvement ofmacular oedema. i He was started on Omega 3RX® on 15/9/10. i Results E.

Since the treatment of Omega 3RX®, the macular oedema has nearly resolved over a period of 2 months. His vision in the left eye has improved from 6/18+1 to 6/18+4.

Two months following Omega 3RX®, the oedema has nearly resolved.

Case 8 Presentation Patient 8 is a 77 year old who had a branch retinal vein occlusion in her only one eye in 8/12/08.

Treatment She was treated with five intravitreal injections of is® and Kenalog® between the periods of 8/12/08 and 09. The effect of resolution of macular oedema with the injection was short lived. Fig. 30 show macular oedema in 5/8/09. Her vision was 6/18, She was started on Omega 3RX® on 3/8/10.

Bfifiyfl Reduction and te resolution of macular oedema following Omega 3RX® treatment was observed (Figures not shown). Vision improved from 6/18 on 5/8/10 to 6/12 on 1/11/10.

Case 9 Presentation Patient 9 is a gentleman who had central retinal vein occlusion in the right eye in October 2007 and presented on 30/1/08. His Visual acuity in the right eye was hand movements on presentation.

Treatment He was treated with ten intravitreal Lucentis® and Kenalog® ions between the periods of 30/1/08 and 3/11/09. He was started on Omega 3RX® on 7/7/10.

Res—HHS Moderate improvements ofmacular oedema was seen following itreal injections but the effect was lasting each time one month approximately. Since the ent with Omega 3RX® the r oedema has much improved. Gradual reduction ofmacular oedema with Omega 3RX® treatment was obseived (Figures not shown). Vision has improved from ng fingers on 7/7/10 to 6/60 on 29/11/10.

Case 10 Presentation Patient 10 is an 82 year old lady who had a cataract surgery in the right eye on 24/11/09 and anterior chamber implant was used due to zonular weakness of the capcular bag. She developed macular oedema following surgery.

Treatment She was treated with steroid and non-steroidal eye drops with no ements of the r oedema. She also had intravitreal injections ofAvastin® and Kenalog® on 26/5/10 and 23/6/10 with no improvement. She was d on Omega 3RX® on 0.

She had te reduction ofmacular oedema following treatment with Omega 3RX®. Less macular oedema was observed following one month of treatment (Figure not shown). Vision improved from 6/36 to 6/18 following treatment.

Case 11 Presentation Patient 1 1 is a 60 year old diabetic gentleman who developed r oedema due to epiretinal membrane in the left eye.

Macular oedema was reduced following one month treatment of Omega 3RX®, Visual acuity also improved from 6/18 to 6/9. Usually epiretinal membranes are treated with surgery involving Vitrectomy with peel of the membrane. This type of surgery has risks of around 5% including retinal ment, cataract, vitreous haemorrhages etc.

Marked reduction of macular oedema was observed (Figure not shown).

Case 12 Presentation Patient 12 is a 67 year old man with diabetes presented with reduced vision in the right eye. On examination he had macular oedema due to diabetes and Visual acuity of 6/1 8.

Treatment He was treated on 12/11/10 with intravitreal lucentis® and g®. His vision improved from 6/18 to 6/9 on 22/12/10. On 28/3/11 he presented with macular oedema and Visual acuity of 6/1 8. He was started on Omega 3RX®.

EELS There was ion ofmacular oedema since the treatment with Omega 3RX®.

Reduction ofmacular oedema from 28/3/11 to 2/5/11 was ed with the Spectralis OCT scan (Figure not shown). Vision improved from 6/18 to 6/9-.

Case 13 Presentation Patient 13 is a 79 old man presented on 1/3/10 with vision of counting fingers in the left eye. On examination he had macular oedema due to wet macular ration.

Treatment He was treated with itreal lucentis® and kenalog® on 31/3/10 and 28/4/10.

He was started on 29/11/10 with Omega 3RX®.

Res—HHS The intravitreal injections resolved the macular oedema temporarily .

Examination on 29/11/10 showed recurrent fluid. On 2/3/11 there was no fluid seen on OCT scan (Figures not shown). Vision improved to 6/60.

Case 14 Presentation Patient 14 is a 60 year old lady presented on 10/1/06 with reduced vision. On examination her vision was 6/24 in the left eye and had macular oedema due to diabetes Treatment She was treated with twelve itreal n® and kenalog® injections in the left eye between 10/1/06 and 19/4/10. She also had focal laser treatments. On 6/5/2008 she had vitrectomy in the lefi eye to try and reduce the oedema which always recurred with the above treatments. On 27/10/10 she was started on Omega3RX®.

Macular oedema was observed despite treatments with intravitreal avastin® and kenalog® injections, focal laser treatments and vitrectomy surgery from the period /11/2008 to 10/1/11 (Figures not shown). Near resolution of oedema after 5 months of ent with Omega3RX® was observed e not shown). Vision improved to 6/9- on 21/3/1 l.

Emma—r3: Macular oedema is often associated with decreased visual acuity and is a frequent cause ofvisual impairment for patients.

Intravitreal administration of steroids/VEGF have been shown to reduce oedema and improve or at least stabilize visual acuity but these effects are often transient. There are also risks involved with injections such as endOphthahnitis, ct, retinal tears, l detachments and high intraocular pressure.

The cases presented show, using OCT scan documentation, that treatment with liquid Omega 3RX® can be of a significant benefit to patients with macular oedema. r thickness can be reduced or even eliminated in ts with r oedema resulting in improvement of Visual acuity. In addition, no ocular or systemic side s were shown. Each patient in this case presentation had a marked and favourable response with reduction in macular oedema during treatment.

Example 3 Improvements have been observed in patients with dry eyes, who were treated with omega fatty acids in the form ofOmega 3RX®.

Example 4 Further case s showing treatment of eye conditions with omega fatty acids Case a) 79 year old female presented on 13.2.12 with left d Vision due to wet AMD (macular degeneration). Visual acuity was 6/60. She was treated with intravitreal Avastin injection and d on Omega 3RX®. One month following treatment there was no fluid on OCT scan and she gained one line of Vision on Snellen chart (Fig. 3).

Case b) 77 year old female ted with right wet AMD on 13.2.12. Her Visual acuity was 6/30. She was treated with itreal Avastin injection and Omega 3RX®. Two months following treatment there was no fluid and she gained six lines of Vision on Snellen chart (Fig. 4).

Case c) 54 year old female had bilateral cataract surgery in November 2008. She ted in July 2001 with reduced Vision due to wet AMD. Visual acuity was 6/60. She was treated with four intravitreal Avastin injections between July and November 2011.

She presented again on 29.2.12 with reduced Vision in the left eye. She was started on Omega 3RX®, and two weeks later there was no fluid with Vision 6/21 (Fig. 5).

Case (1) 61 year old female had twenty three intravitreal Avastin injections for left wet AMD. Her last injection was in June 2011. Her right eye is blind due to retinal detachment. On 30.11.11 she presented with reduced Vision and wet AMD. She was started on Omega 3RX®. Three months following treatment there was minimal fluid with one line gain of Vision (Fig. 6).

Case e) 92 year old male presented in 2009 with right wet AMD. He had three intravitreal Lucentis injections. His left eye is blind. He presented again on 9.1.12 with wet AMD and he was treated with Omega 3RX®. Six weeks following treatment there was no fluid on OCT scan (Fig. 7).

Case 1) 74 year old female presented in April 2011 with right wet AMD. She was treated with intravitreal Avastin injection. She presented again on 19.1.12 with wet r degeneration and Vision of 6/120. She was treated with Avastin intravitreal injection and Omega 3RX®. A month following treatment there was no fluid on OCT and she gained one line ofVision (Fig. 8).

Case g) 60 year old male presented in 2009 with left wet AMD. He was treated with ten intravitreal Lucentis injections. In April 2011 he was d on Omega 3RX®. In November 2011 there was no fluid on OCT scan and he gained four lines of Vision (Fig.

Case h) 76 year old female presented in October 2011 with left wet AMD. She was d with three intravitreal Avastin injections. On 14.2.11 she was started on Omega 3RX® with the last intravitreal n injection. Two months following treatment there was minimal fluid and she gained one line of Vision (Fig. 10).

Case i) 67 year old man presented in 2008 lly with left wet AMD and then with right wet AMD. He had more than twelve intravitreal Avastin injections in each eye. In March 2010 he was started with Omega 3RX®. Two months following treatment there was no fluid in the right eye and gained one line of Vision. Four months following treatment there was no fluid in the left eye and he gained three lines of Vision (Fig. 11).

Case j) 74 year old man presented with left wet AMD in 2008 and right AMD at the end of 2008. He had more than fifteen intravitreal Lucentis injections in each eye. He started on Omega 3RX® on 1.2.11. Four months following treatment there was no fluid on the right eye and he gained one line of vision. In the left eye there was minimal fluid and his Vision was stable (Fig. 12).

Case k) 71 year old man presented with left wet AMD on 1. He was treated with three intravitreal Avastin injectons. His last ion was on 12.1.12 and was also started on Omega 3RX®. Three months following treatment the fluid nearly resolved and he gained one line of vision since the treatment of Omega 3RX® (Fig. 13).

Case 1) 72 year old man presented in 2008 with right wet AMD. He was treated with eight intravitreal Avastin injections the last one at the end of 2010. He presented on 9.1.12 with wet AMD and started on Omega 3RX®. Six weeks ing treatment there was minimal fluid with one line vision gained (Fig. 14).

Case m) 74 year old man presented on 22.2.10 with left wet AMD. He was treated with six intravitreal n injections. On 12.9.1 1 he had the last Avastin injection and started on Omega 3RX®. A month following treatment there was no fluid on OCT scan and he gained two lines ofVision (Fig. 15).

Case n) 43 year old man with right central serous retinopathy. He was treated with three intravitreal Avastin injections and started on Omega 3RX® on 2.12.11. A month following treatment with Omega 3RX® the fluid resolved and he gained two lines of vision (Fig. 16).

Case 0) 60 year old man presented with left wet AMD on 12. He was treated with one intravitreal Avastin injection and Omega 3RX®. The fluid resolved in a month and he gained two lines of vision (Fig. 17).

Case p) 69 year old female presented with left wet AMD on 0. She was treated with nine intravitreal Avastin injections the last one on 27.1.11. She started on Omega 3RX® on 7.12.11. Six weeks following ent there was minimal fluid on OCT scan (Fig. 18).

Case q) 82 year old female presented with right wet AMD in 2007 and lefi wet AMD in 2008. She was treated with more than fifteen intravitreal injections in each eye. She started on Omega 3RX® on 19.10.11. Within two months of starting Omega 3RX® the fluid ed in both eyes. She gained one line of vision in each eye (Fig. 19).

Case r) 74 year old female presented in 2008 with right wet AMD. She had eight intravitreal Lucentis injections. She was started on Omega 3RX® on 19.5.11. The fluid resolved within five months of treatment and she gained one line of Vision (Fig. 20).

Case s) 72 year old male presented with left wet AMD. He had eight intravitreal Lucentis ions, the last one on 5.1.12, also d on Omega 3RX®. Three months following treatment there was no fluid (Fig. 21).

Case t) 72 year old man presented with left wet AMD. He was treated with intravitreal Avastin and was started with Omega 3RX®. Two months following treatment the fluid resolved and he gained four lines of vision (Fig. 22).

Case 11) 72 year old female presented on 22.2.12 with bilateral wet AMD. She was treated with bilateral intravitreal Avastin injections and was started on Omega 3RX®. A month following treatment there was resolution of fluid and she gained one line Vision in each eye (Fig. 23).

Case V) 82 year old male presented with a left eye wet AMD on 9 was treated with four intravitreal Lucentis injections. He presented again on 22.2.12 with left wet AMD and Vision of 6/18. He was treated with intravitreal n and Omega 3RX®, and a month later there was no fluid and he gained one line of Vision (Fig. 24).

Case W) 78 year old female presented with right wet AMD in 2008. She was treated with eleven intravitreal Avastin injections. On 12.12.11 she was started on Omega 3RX®.

Three months following treatment there was no fluid and she gained one line ofVision (Fig. 25).

Case 1:) 63 year old lady with diabetes presented in 2009 with diabetic macular oedema.

She was treated with two introvitreal Avastin injection and two focal LASER ents in each eye. On 7.9.11 she was started on Omega 3RX®. Six weeks following treatment there was no fluid in the right eye and minimal fluid in the left eye. She gained four lines of Vision in the right eye and four lines ofVision in the lefi eye (Fig. 26).

Case y) 58 year old female presented in 2010 with ral macular oedema. She was treated with focal LASER in each eye, two intravitreal Lucentis in the right eye and one intravitreal is in the left eye. She was started on Omega 3RX® on 21.3.11. Four months following treatment the fluid resolved in the right eye and there was minimal fluid in the left eye. She gained four lines of Vision in the right eye and one line ofVision in the left eye (Fig. 27).

Case z) 60 year old man presented in 2006 with ral macular oedema. He was treated with more than ten itreal injections in each eye. Hee also had three sessions of focal LASER treatment in each eye. He was started on Omega 3RX® on 19.12.11. The fluid resolved within two months of treatment and he gained two lines of vision in each eye (Fig. 28).

Case aa) 60 year old man presented with left r oedema in 2011. He was started on Omega 3RX® on 26.9.11. Most fluid resolved within four months and he gained four lines ofvision (Fig. 29).

Case ab) 68 year old man with macular oedema due to diabetes was started on 14.4.11 with Omega 3RX®. Three months following treatment there was l fluid and he gained one line ofvision (Fig. 30).

Case ac) 54 year old female presented in 2010 with bilateral diabetic macular oedema. She had bilateral focal LASER in 2010 and she was started on Omega 3RX® on 7.1.11.

Macular oedema was reduced in both eyes following treatment and she gained one line of Vision in each eye (Fig. 31).

Case ad) 78 year old female presented with left ic macular oedema on 1.6.11. She was treated with intravitreal AVASTIN injection. She was started on oral Omega 3RX® on 23.2.12. Six weeks following treatment the fluid resolved and she gained one line of vision (Fig. 32).

Case ae) 54 year old male had cataract surgery on 24.5.11 and developed d macular oedema on 24.10.11. He was started on steroid and non-steroidal eye drops for one month. On 23.11.11 he was started on Omega 3RX® and two months following treatment the fluid ed (Fig. 33).

Case af) 78 year old female who had complicated cataract surgery in 2010 presented with cystoid macular oedema on 16.1.12. She was started on Omega 3RX® and two months following treatment there was no fluid and she gained one line of vision (Fig. 34).

Case ag) 51 year old female had branch l vein occlusion on 1. She was treated initially with one intravitreal Avastin injection and then with focal LASER on 9.8.11. She was started on Omega 3RX® on 23.11.11. The fluid resolved within three months and the Vision improved by one line (Fig. 35).

Case ah) 78 year old female ted with right branch retinal vein occlusion in 2008. She has prosthesis in the left eye. She was d with four intravitreal lucentis and Kenalog injections. She was started on Omega 3RX® on . There was no recurrence of fluid since then and she gained two lines of vision (Fig. 36).

Case ai) 31 year old man with photoreceptor damage due to chloroquin therapy. He was started on Omega 3RX® on 13.2.12. Photoreceptor thickness increased following treatment and he gained one line of vision (Fig. 37).

Case aj) 68 year old man who had routine cataract surgery in 2009 developed photoreceptor damage. He was started on Omega 3RX® on 29.11.12, three months following treatment with photoreceptor thickness increased and he gained two lines of vision (Fig. 38).

Example 5 New treatment for r oedema and dry eyes The cases ted in this prospective study show that Omega 3RX® in the liquid form (Enerzona) can be of a significant benefit to patients with macular oedema and dry eyes. Each patient in this case presentation had a marked and favourable response with reduction in macular oedema or improvement of dry eyes during Omega 3RX® treatment. The therapy for macular oedema is advantageous to the patient and the clinician compared to the other available treatments. We will now have an opportunity to reduce macular oedema in patients in a way that was not previously possible. The treatment will have a positive impact on a large portion of the population.

OCT (Optical Coherence Tomography) has become an invaluable tool for assessment and therapeutic decision making for patients with macular oedema. It can accurately measure the oedema in the macular area. OCT scans were used to monitor response to treatment in patients.

The y with the Omega 3RX® was given orally 2.5-5ml twice per day in a liquid form. It has been discovered that, if used every day orally on a long term, Omega 3RX® can decrease macular oedema. In addition, no ocular or systemic side effects were seen. This is an alternative therapy to intravitreal injections and laser. To the best of the inventor’s knowledge, there is no other oral treatment effective for macular .

To evaluate the effect of oral Omega 3RX® liquid in eyes with macular oedema secondary to wet macular oedema, diabetic pathy, retinal vein occlusions and following surgery or inflammation and to evaluate the effect of oral Omega 3RX® in dry eyes unresponsive to other treatments.

Method ctive study of 91 eyes with macular oedema started with oral Omega 3RX®. Therapy was given orally twice per day. Each day 5-10mls of Omega 3RX® was used. Macular thickness from OCT scan, Visual acuity and complications were noted.

Also, a prospective study of40 eyes with dry eyes unresponsive to any other ent started on Omega 3RX® orally 51111 twice per day. The state ofthe cornea, visual acuity and patients comments were noted.

There were 4 groups of patients in this prospective study: 1) Group 1 consisted of 45 patients with wet macular degeneration; 2) Group 2 consisted of 34 patients with diabetic maculopathy (retinopathy); 3) Group 3 consisted of 12 patients with branch retinal vein occlusions and cystoid macular oedema secondary to inflammation or surgery; 4) Group 4 consisted of 42 severe dry eye patients unresponsive to current therapies.

Results Group 1: Wet AMD 1. Demographics The sample included 45 patients, 18 females (40%) and 27 males (60%). Their average age was 71.5 years old, ranging from 43 to 92 years, with a standard ion of 9.3 years (Le. 71 529.3). 2. Descriptives of macular oedema thickness per time point.

The average initial thickness of the patients was 483.2, ranging from 235 to 1010, with a standard deviation of 159.0 (483.2i159.0).

The following table shows the minimum, maximum, average (mean) and standard deviation ofthickness at each time point. In addition, the table shows how many ts were measured at each time point (N).

Table 5: ptive statistics of ess at each time point (Wet AMD group) Time Point (Number m Maximum r Std.

Thickness Thickness Deviation —---—— _5-4 —5-4 —9-3 —1-3 Ian-— 0 167 395 278.00 81.930 Note: The reduction in mean oedema thickness at each time point in relation to initial measurement is statistically significant at the 5% level (p<5%) (for all time points where paired samples t-test was used). The descriptive statistics in Table 5 show that thickness has reduced, on e, at each time point, in relation to the initial measurement.

To get a better insight of the ion in thickness, ptive statistics ofthe reduction in on to initial thickness were obtained. All the descriptive statistics (mean thickness at each time point, standard deviation, number ofpatients measured at each time point) are given in Table 6.

Table 6: Descriptive statistics of thickness at each time point (Wet AMD group) Mean Thickness at each time Number of point? patients Std. Deviation l'airl IITIALTHICKNESS 483.18 158991 IIITIAL THICKNESS 491.69 166.468 U) H359m 350.54 127.865 |' air 3 I ITIAL THICKNESS 490.32 154.922 _‘ (I! 1 315.71 118.565 air 4 I ITIAL THICKNESS 525.24 184.398 O‘\ H*31’3H.53‘ 303.88 116.239 air 5 I ITIAL THICKNESS 588.70 10 139.003 .\l U] gOa:r‘(A 278.00 81.930 |' air 6 ITIAL THICKNESS 602.50 " 124.681 9months 261 .75 u 77 .987 r air 7 1 ITIAL THICKNESS 580.50 _ 139.167 , 10.5months 243 .33 “ 82.452 air 8 1 HIAL THICKNESS 676.00 - lZmonths 222.25 _ air 9 I ITIAL THICKNESS 730.50 1 8months 198.50 *Notice that this is the mean thickness ofthe patients that were measured at both time points (for example at time point “3 months” 39 patients were measured, so we have the mean of those 39 patients, both at initial ement and at 3 months. That is why the mean of the initial thickness s at each time point (it depends on how many patients were measured at the corresponding -up time point of interest) (e.g. for 3 months we have the mean initial ess of 39 patients (now 491.69 instead of 483.18 which was for 45 patients).

In addition, paired samples t-tests were med, to examine whether the reduction of thickness at each time point in relation to the initial measurement was statistically significant at the 5% level of significance. A ion is considered statistically significant if the corresponding p-Value is lower than 5%. All the results of the paired samples t-tests appear in Table 7.

Table 7: Paired samples t-tests to examine for significant reduction in thickness at each time point (Wet AMD . 95% Confidence Mean Std. ion Interval ofthe Mean Reduction in ofreduction in Thickness Thickness thickness Lower Upper T df . -va1ue _- 93.1rII ITIAL-6II-97.156 106.237 65.239 129.073 6.135 44 0.001 U 9t1rII ITIAL- 3 141.154 155.325 90.803 191.504 5.675 U.) _OOO,_.

' II- —' 93.1rIII--ITIAL- 174.613 144.780 121.507 227.719 6.715 U.) InU 93. II lTIAL-6 221.353 179.933 128.840 I—‘ 9OO,_. 313.866 5.072 A I.- _I 9K1rII ITIAL—I--310.700 181.500 180.863 440.537 5.413 I I 9’.it" lTIAL—9II-340.750 176.436 193.246 488.254 5.463 \1 .Ooo,_. 1 I39_11‘"I--TIAL- 337.167 208.058 118.823 555.510 ‘fian" lTIAL—I--453.750 118.402 65.239 129.073 N/A I / Z5> an" ITIAL— 532.000 8 90.803 191.504 N/AI / z> \o II- Reduction is significant at the 1% level of significance (p<1%) tion is cant at the 5% level of significance (p<5%) Conclusions from the previous tables regarding the reduction in thickness: Looking at the above s, it can be seen that a reduction in oedema thickness has been shown statistically, since the mean ion in thickness was positive at all time points and additionally the paired samples t—tests showed that this reduction was significant (all p-Values were lower than 5%) (i.e. difference between l and new thickness was significantly different from zero and positive). In addition the reduction was increasing from each time point to the next, starting from a mean reduction of 97.156 at 6 weeks and reaching a mean reduction of 532 at 18 months tion of this was at .5 months, where although there was a significant reduction (p=0.011<0.05) the level of reduction did not increase, it was lower compared to the previous time points, 337 compared to 340) (see the column “Mean reduction in thickness” in the above table;).

Overall, the above results show that ts at each time point had, on average, cantly lower levels of thickness compared with the initial measurement and they had even more improvement as time went by.

Initial Vision and Gain in Vision (number of lines gained) Table 8 below provides descriptives of initial Vision.

Table 8 Frequency l Vision (Number ofpatients) 11.1 6/4.5 100.0 From the above table, it can be seen that most of the patients had very problematic initial vision. More specifically, 20% of patients had Vision of 6/60 and 13.3% had vision of 6/120, While another 13.3% had vision CF. Only 2.2% had Vision of 6/4.5.

Table 9 below shows the gain in lines for patients at different time points-WET Table 9 Lines 6 weeks 3 months 4.5 6 months 9 months 18 gained months (N=21) (N=1 0) months f f % (N=2) f % f % f % _---——m ------m It can be seen that at 6 weeks, 20 patients (44.4%) had no gain in lines, but at later time points the percentage of zero gain decreases substantially, while on the contrary the percentage of patients with gain in 2 lines ses as time goes by.

The raw data regarding gains in lines were further examined, and the mean gain in lines at each time point were plotted, as shown in Figure 39. From Figure 39 it can be seen that on average there is a gain in lines of vision (all means are positive) and this gain in lines increases as time goes by.

Figure 40 shows the comparative distributions for each number of lines of vision gained. More specifically it shows the number of ts that had a gain of zero lines at each time point (6 weeks to 18 months), and similarly for a gain of 1 line at each time point, for 2 and 3 or more lines.

It can be seen that at 6 weeks, most ts had no gain in lines (see blue bars) whereas at 3, 4.5 and 6 months most patients had gain of 1 line, while at 9 and 12 months most ts had gain of 2 lines (see yellow and red bars). Overall, no patient had zero gains in lines after 9 months (i.e. at 9, 12 or 18 months- no red or light blue at zero).

It was ed whether there is a relation between initial vision and number of lines gained (i.e. ifpeople that stated with a better vision had more improvement) and we see also how this improvement is through time (from 6 weeks to 18 ). In order to test it with chi-square tests, to see if the relation is statistically significant, ng of initial Vision categories was deemed ary, due to the small number of patients in each cell. ng of initial Vision in categories was 0=up to 6/30, 1=between 6/24 and 6/15 and 2=better than 6/12. Each of the graphs in Figure 41 corresponds to one timepoint. The p—Value from the chi-square test is as follows (6 weeks P=0.402 > 5%; 3 months P=0.823>5%; 4.5 months P=0.731>5%; 6 months P=0.436>5%; 9 months, P=0.761>5%; 12 months, P=0.323>5%) If p<0.05 it means that it matters how the initial Vision was in terms of the number of lines gained, otherwise the number of lines gained does not depend on the initial vision of the patient. In all the cases, p was larger than 5%.

Number of injections in on to Omega 3RX® therapy 1. Previous injections: For the 45 patients of Wet AMD, the mean number ofprevious injections was 6.6, with a standard deviation of 5.3: Table 10 --II-Number of Std.

I umber ofprevious_-WII-45 25 .00 6 .5556 5.27669 The following table shows the distribution of the number ofprevious injections (number/percentage of patients who had each number of injections).

Table 11 Number of injections Number of patients % of patients -Total patients: 45 100% Number of months that patients had their last ion before starting Omega 3RX® Treatment: Mean=4.5 months and standard deviation 6.7 months before Omega 3RX®. More s: Table 12 N\O OO- (Note that one patient did not have an injection before or at STAT with Omega 3RX® Treatment, so they are not included in the above sample) In more detail: Number ofmonths that patients had their last injection before starting Omega 3RX® Treatment: Table 13 Last injection to initial Omega 3RX® (months) Number of patients % ofpatients STAT 1-3 months 4-6 months 8-12 months More than 1 year Total patients: 44 (1 patient did not have an injection before or STAT with Omega 3RX®) WET AMD: Number of Avastin injections during treatment with Omega 3RX®.

Table 14 Number ofinjections Number ents % ofpatients From the above table it can be seen that most of the patients (64.4%) did not have an injection during their treatment with Omega 3RX®.

The results (about previous and current injections) were put in one table and graph, which shows the time of the previous ions before-STAT or during treatment in relation to the number of injections. The total number of injections can be considered (previous injections + STAT+ during treatment for every patient). Note that since some patients had some injections before and some injections at STAT or during treatment, the table shows the time of the last injection for all patients.

Table 15 Time of last injection Before During ent STAT treatment Total I umber oftotal I umber ofpatients 38.5° 385° 23.1010000 -6injections umber ofpat1ents - H H 54.5% 36.4- 100.0°. 7-12myect1ons I umber ofpatients --- ore than 15 I umber ofpatlents U..-“ I umber ofpat1ents _--— From the table it can be seen that most ts who had a lot of injections had them before their treatment with Omega 3RX®.

It can be examined how many ofthe patients who needed a lot of injections before their treatment with Omega 3RX® reduced their number of injections during their treatment. This is given by a cross tabulation: Table with grouped ries: Table 16 Avastin during Omega 3RX® ._. to Total o )—A 1—4 \1 ‘ 1—4 II H o; I; A H H s o I r—t — E?:3 1—1 0 o From the above tables, looking at the 29 patients ) who did not need any injection during their therapy with Omega 3RX®, most ofthem (17 patients or 59%) were those that had had a lot ofprevious injections (6.g more than 7). It appears that the number of Avastin injections is reduced cantly during therapy with Omega 3RX®.

It was examined r the gain in lines of vision is related with the number of injections during Omega 3RX® treatment, at the various timepoints. A uous variable “average gain in lines”, which is the average gain in lines over all the time points (6 weeks, 3 months etc.) that data for each patient is available, was created. 1. Gain in lines in relation to injections during Omega 3RX® treatment: An independent samples t-test was performed, Where the p—Value was found to be 0.494. This means that on average it does not affect the gain in lines whether a t has an Avastin ion during the treatment or not. The mean gain in lines is similar for the two groups (1.07 for those who did not have any injection during the treatment and 1.25 for those who had an injection) (Notice that although 1.25 is higher than 1.07 the results of the test show that this difference is not statistically significant).

Table with results from t-test for relation between gain in lines of vision and Avastin injections during Omega 3RX® treatment.

Table 17 Avastin® injections Mean during Omega 3RX® gain in treatment 2. Gain in lines in relation to number of previous injections e Omega 3Rx ent): The raw data (i.e. not grouped in categories, as given for each patient, e.g. 8, 15 etc.) for the number of previous injections was used and examined with Pearson’s correlation coefficient, if the number ofprevious injections affects the average gain in lines. The results showed that the number ofprevious injections affects the gain in lines negatively (Pearson’s correlation coefficient is equal to -0.354, p-value=0.017<5%). In other words, if a patient had a lot of previous injections before the ent then he/she will have on average a lower gain in lines of vision (or if he did not have a lot of previous injections then he will have on average a higher gain). This was further investigated when the data for the number ofprevious injections were now grouped in categories (0-3, 4—6, 7—12, more than 15), using one—way ANOVA and post-hoe Tukey tests. The tests showed that the previous conclusion did not hold for all the levels of previous injections, but a (marginally) significant difference in gains in lines existed only between the patients that had 4-6 previous injections and those that had more than 15 injections, (p=0.069<10%). More specifically, those who had more than 15 previous injections had on average lower gain in lines compared to those that had 4-6 injections (0.38 lines compared to 1.45 lines tively). So, the group that had the t mean gain in lines was those who had 4-6 previous ions (ifwe compared those with 4-6 injections with those in the group 0—3 injections and 7—12 injections, the ences were not, however, statistically significant (p-values 0.967 and 0.595 tively, both larger than 5%).

Notice, of course, that for all four groups ofprevious injections the mean gain in lines is positive (so they all had a gain), and the e gain in lines for all patients was 1.14. The next table gives all the descriptive details.

Table: Number of previous injections in relation to gain in lines of vision Table 18 Number ofprevious 'Mean gain in lines o injections vision Group 2: CSMO (Clinically significant macular oedema in patients with diabetic retinopathy) 1. Demographics The sample included 34 patients (10 females, 22 males and 2 patients t a record of gender). Their average age was 64.6 years old, ranging from 53 to 79 years, with a standard deviation of 7.5 years (i.e. 64.6i7.5). 2. Descriptives of thickness per time point.

The average initial thickness ofthe ts was 511.9, g from 167 to 841, with a standard deviation of 180.3 (511.9:E180.3).

The following table shows the m, maximum, average (mean) and standard deviation ofthickness at each time point. In addition, the table shows how many patients were measured at each time point (N).

Table 19: Descriptive statistics of thickness at each time point (CSMO group).

Mean macular Time Point oedema Std.

Deviation The results for mean thickness show that on e there is a reduction in thickness for all time points in relation to the initial thickness. Note: Reduction in relation to initial measurement is tically significant at the 5% level (p<5%) (for all time points where paired samples t—test was used). The descriptive tics in Table 20, show that thickness has reduced, on average, at each time point, in on to the initial measurement.

To get a better insight of the reduction in thickness, descriptive statistics of the reduction in relation to initial thickness were ed. All the descriptive statistics (mean thickness at each time point, standard deviation, number of patients measured at each time point) are given in Table 20.

Table 20: Descriptive statistics of thickness at each time point (CSMO group) Mean Thickness at each time Number of point patients Std. Deviation Pair 1 I ITIAL THICKNESS 511.91 34 180.286 6 weeks 445.18 34 1 ’ 1' air 2 I ITIAL THICKNESS 499.52 31 186.272 3 months 410.00 31 192.188 Pair 3 I ITIAL THICKNESS 536.96 24 161.380 ‘ .5 months 405.71 24 180.619 I' air 4 I ITIAL THICKNESS 604.00 11 160.789 0‘ Hga:rm 495.36 185.335 Pair 5 l ITIAL THICKNESS 556.75 117.831 >1“goaE‘(I) 474.50 155.941 'air 6 I ITIAL THICKNESS 523.14 141.029 E?gE.r([1 391.14 151.413 lair 7 I ITIAL THICKNESS 556.75 117.831 .Smonths 297.75 93.128 Pair 8 I ITIAL THICKNESS 479.00 110.309 In addition, paired samples t—tests were performed, to examine whether the reduction of thickness at each time point in relation to the initial measurement was statistically significant at the 5% level of significance.

Table 21: Paired s t—tests to examine for significant reduction in thickness at each time point (CSMO group) . 95% Confidence Interval of the ' ' Mean Thickness hickness thickness Lower Upper t df e aiI ITIAL- 66.735 94.276 33.841 99.630 II.128 33 0.001 IIIIIIIII'aill lTIAL- 89.516 101.930 52.128 126.904 .890 30 0.001 I’aiIl ITIAL-IIII-IIII131.250 121.081 80.122 8 5.310 23 0.001 I'aih... III-IIIII lTIAL- 108.636 135.701 17.471 199.802 '.655 10 0024* al'iIIII-II lTIAL- 82.250 165.210 -180.636 345.136 I /A I / N/A II-II lTIAL— 132.000 135.773 6.431 257.569 r 572 0.042 I’aiIII--II lTIAL- 259.000 161.086 2.676 515.324 I /A \ p Pai II ITIAL— 200.500 246.780 33 2417.733 I /A I / N/A 8 12 months Reduction is significant at the 5% level, p<5% for all time points ~Note that the statistical test is not valid for 7.5, 10.5 and 12 months due to the small number of patients, and thus the e is not reported).

Conclusions from all the previous tables, regarding the reduction in thickness: Looking at the above results, it can be seen that a reduction in oedema ess has been shown statistically, since the mean reduction in ess was positive at all time points and additionally the paired samples t-tests showed that this reduction was significant (all p-values were lower than 5% at the time points for which the paired s t—test was performed and was valid).

Overall, the above results show that patients ofthe CSMO group, at each time point had, on average, significantly lower levels of thickness compared with the initial measurement.

Initial Vision and Gain in Vision (number of lines gained) The following table provides descriptives of initial vision for the CSMO group.

Table 22 __—(Number4ofpatients) __—118 _-_85 __—UJ 6/18 _—3 _—U.) — From the above table, it can be seen that most of the patients had problematic initial vision, where 11.8% had vision of 6/120 and 23.5% 6/60.

Table 23 shows the gain in lines for patients at different time points-CSMO Table 23 Lines 3 months 4.5 months 6 months 9 months 10.5 12 months gained (N=30) (N=24) (N=1 3) (N=8) months (N=2) f % f % f % f % (N=4) r % f % _——---—m --—---—m.l . . . 2 -413.3 2 15.4 1 12.5 0 0.0 1 50.0 3or 2 5.9 6 20.0 6 25.0 3 23.1 1 12.5 1 25.0 1 50.0 more The raw data regarding gains in lines were further examined, and the mean gain in lines at each timepoint were plotted, as shown in Figure 42. From Figure 42 it can be seen that on e there is gain in lines (all means are positive) and the gain constantly increases slightly as time goes by (there is a large increase at 12 months, but there are only have 2 patients for that time point).

Figure 43 shows the ative butions for each number of lines of vision gained. More specifically it shows the number of patients that had a gain of zero lines at each time point (6 weeks to 12 months), and similarly for a gain of 1 line at each time point, for 2 and 3 or more lines.

The relation between initial vision and number of lines gained can now be examined (i.e. if people that started with a better vision had more improvement) and it can be seen also how this improvement is through time. Grouping of initial Vision in categories was 0=up to 6/30, l=between 6/24 and 6/15 and 2=better than 6/12. The graphs for the time points which had an adequate number ofpatients for presentation are shown in Figure 44. The graphs of Figure 44 show that there is no relation between initial Vision and gain in lines. To explain this in simple words: for example, looking at the graph for 4.5 months, it appears that it does not make a difference if a patient started with a very bad initial vision (up to 6/30) in terms of the gain in lines (e.g. we expected maybe that if someone started offwith a good vision that he would get more lines , or if he started with a bad Vision that he would get fewer lines , but none of the two seems to be true). In general, good or bad initial vision does not seem to be related to gain in lines.

Number of injections in relation to Omega 3RX® therapy 2. us injections: For the 34 patients of CSMO, the mean number of previous injections was 3.5, with a standard deviation of 3.7: Table 24 fpreviousinjections 12.00 3.71116 The following tables and the pie chart show the distribution ofthe number of previous injections (number/percentage of patients who had each number of injections).

Table 25 Number of injections Number of patients % of patients 0 7 1-2 15 6-7 7 210 5 Number of months that patients had their last injection before starting Omega 3RX® Treatment: Mean=l4.7 months and standard deviation 13.7 months before Omega 3RX®.

More details: Table 26 I umber ofpat1ents (Notice that 7 patients did not have an injection before or at STAT with Omega 3RX® ent, so they are not included in the above sample) In more detail: Number of months that they had their last injection before ng Omega 3RX® Treatment: Table 27 Last injection to initial Omega 3RX® (months) Number of patients % of patients STAT 1 . 1-4 months 6-9 months 1-2 years 3-4 years Total patients: 27 (7 patients did not have an injection before or STAT CSMO: Number of Avastin® injections during treatment with Omega 3RX®.

Table 28 0 85.3 _'__ From the above table it can be seen that most of the ts (85.3%) did not have an injection during their treatment with ®.

Focal laser: the following table shows the number of times that patients in the CSMO group had focal laser.

Table 29 Number oftlmes of focal laser Number ofpatlents Regarding the time of doing focal laser, of those who had done laser (i.e. 22 patients), 19 patients (86%) had done it before treatment, 2 patients (9%) after the treatment and for one patient the dates of focal laser treatment were not available.

It can be examined how many ofthe patients who needed a lot of injections before their ent with Omega 3RX®, reduced their number of injections during their treatment. This will be given by a cross tabulation and a graph.

Table with grouped categories: Table 30 From the above table, looking at the 29 patients (85.3%) who did not need any injection during their therapy with Omega 3RX®, 7 (24%) had had 6-7 previous ions. It appears that the number of Avastin injections is reduced significantly during therapy with Omega 3RX®.

It can be examined whether the gain in lines of vision is related with the number of injections before and during Omega 3RX® ent, at the various timepoints.

Gain in lines in relation to injections during Omega 3RX® ent: An independent samples t-test was performed, where the p-value was found to be 0.129. This means that on average it does not affect the gain in lines whether you have an Avastin injection during the treatment or not. The mean gain in lines was 1.27 for those who did not have any injection during the treatment and 0.57 for those who had an injection, but according to the statistical test this ence is not significant (p=0.129>5%) Table with results from t-test for relation between gain in lines of vision and Avastin injections during Omega 3rx treatment.

Table 31 during Omega 3RX® of III-gain in ---——— —--—— Gain in lines of vision in relation to number of previous injections wefore Omega 3RX® treatment): The results showed that the number ofprevious injections is not cantly related to the gain in lines (Pearson’s correlation coefficient is equal to , p- value=0.029<5%). In other words, it does not make any difference how many injections the patient had before the treatment in terms of the gain in lines of Vision that he will have.

Similar results were obtained using a one-way ANOVA test when treating the number ofprevious injections as ries (p-Value=0.l61>5%), which again shows that the number ofprevious injections does not affect the gain in lines of .

Group 3: OTHER (4 eyes with BRVO (Macular oedema in patients with branch retinal vein occlusion) and 8 eyes with CMO (Patients with cystoid macular oedema) 1. Demographics The sample included 12 ts (6 females, 6 males, 50% each group). Their average age was 53.8 years, ranging from 10 to 78 years, with a standard deviation of 23 years (i.e. 53.8i23). 2. ptives of thickness per time point.

The average initial thickness ofthe patients was 510.33, ranging from 307 to 820, with a standard deviation of 155.5 (510.3:t155.5).

The following table shows the minimum, maximum, average (mean) and standard ion ofthickness at each time point. In addition, the table shows how many patients were measured at each time point (N).

Table 32: Descriptive statistics of thickness at each time point.

N Mean (Number macular Time Point of m Maximum oedema Std. patients) Thickness Thickness Thickness Deviation —-12 820 510.33 155.522 —-12 767 416.75 155.682 -n 694 342.22 162.286 —-7 719 324.00 195.371 —-4 337.25 242.040 -3 618 351.00 232.858 -2 245 217.50 38.891 256 223.00 46.669 190 190.00 190 190.00 The descriptive statistics in Table 32 show that thickness has reduced, on average, at each time point, in on to the initial measurement.

To get a better insight of the reduction in thickness, descriptive tics of the reduction in relation to initial thickness were obtained. All the descriptive statistics (mean thickness at each time point, standard deviation, number ofpatients measured at each time point) are given in Table 33.

Table 33: ptive statistics of thickness at each time point (other group) Mean ess at each time Number of point patients Std. Deviation I'airl I ITIAL THICKNESS 510.33 155.522 155.682 |' air 2 l ITIAL THICKNESS 493.00 n 149.044 342-” " 6 I'air3 IITIALTHICKNESS 514.14 161.711 __-. .5 months 324.00 7 195.371 I'air4l1TIALTHICKNESS 560.75 208.674 air5 THICKNESS 563.00 255.513 I- air 6 1TIAL THICKNESS 434.50 177.484 I'air7 llTIALTHICKNESS 434.50 4 .5months 223.00 46.669 I'air8 IlTIALTHICKNESS 309.00 IIITIALTHICKNESS 309.00 1 n/a In addition, paired samples t-tests were performed, to examine whether the reduction ofthickness at each time point in relation to the initial measurement was statistically significant at the 5% level of significance.

Table 34: Paired samples t-tests to examine for significant reduction in thickness at each time point (other group) 'airll ITIAL-6 93.583 7 29.254 157.913 3.20211 0.008 1 eeks I-I-l-IilI'a1rIl ITIAL-3 150.778 85.834 84.800 5 5.270 0.001 I’airl III-I.“-190.143 87.068 109.619 7 5.778 0.001 I_----IIII'a1rll 1T1AL-6 223.500 119.651 33.109 413.891 3.736 3 0.033 I_----Iil'airl ITIAL-7.5 212.000 98.382 -32.394 456.394 n/a / n/a l ITIAL—9III-Ili-217.000 138.593 n/a n/a n/a :/- n/a I-I-l-IiIalirl lTIAL- 211.500 130.815 963-824 1386.824 n/a / n/a I----IiII'a1rll ITIAL 12 n/a | n/a 18 months Reduction is significant at the 5% level, p<5% for all time points where the paired samples t-test was performed —Note that the statistical test is not valid for 7.5, 9, 10.5, 12 and 18 months due to the small number of patients, and thus the p-value is not reported).

Conclusions from all the previous , regarding the reduction in thickness: Looking at the above results, it can be seen that a reduction in oedema thickness has been shown statistically, since the mean reduction in thickness was positive at all time points and onally the paired samples t—tests showed that this reduction was significant (all p-values were lower than 5% at the time points for which the paired samples t—test was performed and was valid), in relation to the initial thickness.

Overall, the above results show that patients of the other group, at each time point had, on average, significantly lower levels of thickness compared with the initial measurement.

Initial Vision and Gain in Vision (number of lines gained) The following table provides ptives of initial vision for the other group. The same results appear also graphically below, with a bar chart.

Table 35 Frequency Initial Vision r of1patients) 6/36 33.3 Table 36 shows the gain in lines for patients at different time points-OTHER Table 36 Lines 6 weeks 3 months 4.5 9 months 18 months _ (N=3) months f(N=70) (N=1) _--mmmmm -—-_-_mm —--___mm -m-_-_--3 or more 2 22.2 14.3 25.0 33.3 100.0 1 100.0 It can be seen from the table that at 6 weeks 25% of patients had no gain, but this number was reduced to zero after 3 months.

The raw data regarding gains in lines were further examined, and the mean gain in lines at each time point were plotted, as shown in Figure 45: Figure 46 shows the comparative distributions for each number of lines of vision gained. More specifically it shows the number of patients that had a gain of zero lines at each time point (6 weeks to 18 months), and rly for a gain of 1 line at each time point, for 2 and 3 or more lines.

It can be seen from Table 36 and Figures 45 and 46 that patients had more gain in lines of Vision as time went by. More specifically we can see how the zero gain disappears after 3 months and how the gain of 3 or more lines increases.

Number of injections in relation to Omega 3RX® therapy 3. Previous injections: For the 12 patients of the other group, the mean number ofprevious injections was 2.2, with a standard ion of 3.4: Table 37 I umber ofprevious injections-m-I 3 .4333 The following tables show the bution of the number ofprevious injections (number/percentage of ts who had each number of injections).

Table 38 Number of injections Number of patients % of patients 0 6 l 2 2 l 4 l 8 l 8.3 1 8.3 _Total patients: 12 100% Number of months that patients had their last injection before starting Omega 3RX® Treatment: Mean=4.3 months and standard deviation 2 months before Omega 3RX®. More s: Table 39 (Notice that 6 patients did not have an injection before or at STAT with Omega 3RX® Treatment, so they are not included in the above ) Number of months that they had their last injection before starting Omega 3RX® Treatment: Table 40 Last injection to initial Omega 3RX® (months) Number of patients % of patients —Total patients: 6 100% ents did not have an injection before or STAT with Omega 3RX®) Other group: Number of Avastin® injections during treatment with Omega 3RX®.

None ofthe patients in this group had an injection during treatment with Omega 3RX®. Therefore either the number of injections remained the same (for those who had no previous injections they did not have any during the treatment either) or it was reduced to zero (for those that had some injections before the treatment).

It can now be examined whether the gain in lines of vision is related with the number of injections before Omega 3RX® treatment, at the various timepoints.

The continuous variable “average gain in lines”, which is the average gain in lines over all the time points that we have data for each patient, was created.

The results showed that the number of previous injections is not related to the gain in lines (correlation coefficient is equal to -0.242, p-value=0.448>5%). In other words, it does not matter how many injections the patient had before the treatment in terms of the gain in lines of vision that he will have.

Similar s were obtained using a one-way ANOVA test when treating the number of previous injections as categories (p-value=0.405>5%), which again shows that the number ofprevious injections does not affect the gain in lines of vision.

Group 4 : Severe Dry Eyes A1140 eyes with dry eyes unresponsive to any other ocular treatment showed improvement between 70-90% ofthe cial punctate keratitis and tear break up time after 1 month following treatment with Omega 3RX®. Also patients reported marked improvement of the s, watering and n body sensation of their eyes within 1 month of treatment.

These patients had been treated for long periods oftime with most of the t therapies available in the market such as d eye drops, artificial tear drops and oinmtents, Restasis® eye drops, punctual plugs, other omega 3 supplements etc. with no relief of their symptoms.

The following table shows the fication of dry eyes. The patients had most of the symptoms and signs of severity score 3 and 4 (moderate to severe dry eyes).

Table 41 _Dry eye ty grading scheme -----Dry Eye Severity 1 2 3 Discomfort, Mild and/or Moderate episodic Severe frequent or Severe and/or severity and episodic; occurs or chronic, stress constant without disabling and frequency under or no stress stress constant environmental stress Visual symptoms None or episodic Annoying and/or Annoying, chronic nt and/or mild fatigue activity—limiting and/or constant, possflaly disabling episodic ng activity Conjunctival None to mild None to mild +/— +/+ + injection ----Conjunctival None to mild Variable Moderate to Marked Corneal staining None to mild Variable Marked central Severe punctuate Corncal/tear None to mild Mild debris, Filamentary Filainentary signs V meniscus keratitis, mucus keratitis, mucus clumping, A tear clumping, A tear debris debris, tion Lid/meibomian MGD variably MGD variably Frequent Trichasis, present t - keratinization, symblepharon er score Variable s 10 s 5 g 2 (mm/5 min) *Must have signs and symptoms. TFBUT:fluores cein tear break-up time. MGD: meibomian gland disease The table above shows : The Definition & Classification ofDry Eye Disease Guidelines from the 2007 International Dry Eye Workshop Discussion Oral Omega 3RX® appears to be an effective treatment for macular oedema secondary to wet macular degeneration, diabetic pathy, retinal vein occlusions and following surgery or inflammation. Eyes treated with oral Omega 3RX® showed a significant reduction in macular thickness and improvement in visual . Also treatment for severe dry eyes with Omega 3RX® has been shown to produce marked improvement of signs and symptoms ofthe patients. Treatment seems to be well tolerated with no systemic side effects.

The case studies have shown using OCT scan documentation that, using Omega 3RX® in the liquid form as monotherapy or sometimes in combination with EGF injections in patients with macular oedema macular thickness can be reduced or even eliminated in patients with macular oedema ing in improvement of visual acuity. In addition no ocular or systemic side s were shown.

There is continued reduction of macular oedema for patients taking the RX®. Significant reduction over the following months for patients who continue with the ent has been shown.

Dry eye is one ofthe common disorders encountered in al practise. Ocular surface inflammation is considered an important pathologic factor of dry eye. Patients with dry eyes (moderate to severe dry eyes) who were unresponsive to other treatments have shown improvements after using Omega 3RX®.

Treatment with Omega 3RX® appears to be safe and effective in te to severe chronic dry eye.

Omega 3RX® liquid is recommended to be used in the following diseases: 0 Age related macular degeneration (wet type) 0 Diabetic pathy o Retinal vascular occlusions (branch or central) 0 Cystoid macular oedema following surgery or inflammation 0 Other causes of oedema such as central serious retinopathy, RPE atrophy 0 Dry age related r degeneration to prevent the risk from developing to wet. a Dry eyes Oral treatment is a huge advantageous to the patients compared to monthly expensive intravitreal injections.

In some cases, monotherapy may need to be the only treatment. The aim of treatment is to se outcomes and minimise side effects. Always the desired end result should be a flat retina Without continuous retreatments. Combination therapies may provide better l outcomes for some patients.

Claims (19)

Claims

1. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or a salt or an ester thereof, formulated for use in the treatment of a condition selected from the group consisting of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5: 1.

2. Eicosapentaenoic acid and hexaenoic acid as d in claim 1, n the condition is macular oedema or dry eyes.

3. Eicosapentaenoic acid and docosahexaenoic acid as claimed in claim 1 or claim 2, 15 wherein the condition is macular oedema.

4. pentaenoic acid and docosahexaenoic acid as claimed in claim 3, wherein the macular oedema is caused by or associated with wet age—related macular degeneration, diabetic retinopathy, retinal vascular occlusion and/or ation of the eye.

5. Eicosapentaenoic acid and docosahexaenoic acid as claimed in claim 3 or claim 4, wherein the eicosapentaenoic acid and docosahexaenoic acid are formulated for use in the ent of a patient population that is poorly responsive or non responsive to treatment with a VEGF inhibitor.

6. Eicosapentaenoic acid and hexaenoic acid as claimed in claim 1 or claim 2, wherein the condition is dry eyes.

7. Eicosapentaenoic acid and docosahexaenoic acid as claimed in claim 6, wherein the 30 condition is moderate or severe dry eyes.

8. Eicosapentaenoic acid and docosahexaenoic acid as claimed in claim 6 or claim 7, wherein the eicosapentaenoic acid and docosahexaenoic acid are formulated for use in the treatment of a t population that is poorly responsive or non responsive to treatment with steroid eye drops, artificial tear drops, tear lubricating ointments, steroid nts, punctual plugs and/or cyclosporine eye drops.

9. Eicosapentaenoic acid and docosahexaenoic acid as claimed in claim 1, wherein the condition is a ion g damage to retinal photoreceptors and/or retinal t epithelial cells selected from the group ting of retinitis pigmentosa, Stargardt’s 10 disease, damage caused by exposure to extreme light, damage associated with surgery, damage associated with exposure to chemical toxins, macular dystrophy and dry age- related r degeneration.

10. Eicosapentaenoic acid and docosahexaenoic acid as claimed in any one of claims 1 to 15 9, wherein the wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 2:1 to 2.4: 1.

ll. Eicosapentaenoic acid and docosahexaenoic acid as claimed in any one of claims 1 to 10, n the dosage of eicosapentaenoic acid is from 4 mmol to 15 mmol per day and 20 wherein the dosage of docosahexaenoic acid is from 2 mmol to 7.5 mmol per day.

12. Eicosapentaenoic acid and docosahexaenoic acid as claimed in any one of claims 1 to 11, er with a further therapeutic agent, for simultaneous, sequential or separate administration.

13. Eicosapentaenoic acid and docosahexaenoic acid as claimed in claim 12, wherein the r therapeutic agent is selected from the group consisting of a VEGF inhibitor, a steroid, a carbonic anhydrase inhibitor, and cyclosporine. 3O

14. A composition according to claim 1 and further comprising at least one pharmaceutically acceptable excipient, formulated for use in the treatment of a condition selected from the group ting of r oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal.

15. The composition as claimed in claim 14, wherein the composition is for oral stration.

16. The ition as claimed in claim 14 or claim 15, wherein the composition ses at least 50 weight % omega—3 fatty acids. 10

17. The composition as claimed in any one of claims 14 to 16, wherein the composition is substantially free from anti-oxidants.

18. The composition as claimed in any one of claims 14 to 16, wherein the composition consists of, per 100g: Fats 100 g Of which: Saturated 3.1 g Monounsaturated 11.5 g Polyunsaturated 85.4 g Total omega—3 fatty acid 75 g Of which: EPA (eicosapentaenoic acid) [40 g DHA (docosahexaenoic acid) 20 g Other omega—3 fatty acid 15 g

19. A kit comprising i) eicosapentaenoic acid and docosahexaenoic acid, or a salt or an ester thereof, as described in any one of claims 1, 10 and 11, and 20 ii) a further therapeutic agent selected from the group consisting of a VEGF inhibitor, a steroid, a carbonic anhydrase inhibitor, and cyclosporine, the kit being characterised in that it is ctured for use in the treatment of a condition selected from the group ting of macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal.